Free Trial

Reviva Pharmaceuticals (RVPH) Stock Forecast & Price Target

Reviva Pharmaceuticals logo
$2.59 -0.02 (-0.77%)
(As of 01:27 PM ET)

Reviva Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
1
Buy
3

Based on 4 Wall Street analysts who have issued ratings for Reviva Pharmaceuticals in the last 12 months, the stock has a consensus rating of "Buy." Out of the 4 analysts, 1 has given a hold rating, 2 have given a buy rating, and 1 has given a strong buy rating for RVPH.

Consensus Price Target

$15.50
498.46% Upside
According to the 4 analysts' twelve-month price targets for Reviva Pharmaceuticals, the average price target is $15.50. The highest price target for RVPH is $17.00, while the lowest price target for RVPH is $14.00. The average price target represents a forecasted upside of 498.46% from the current price of $2.59.
Get the Latest News and Ratings for RVPH and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Reviva Pharmaceuticals and its competitors.

Sign Up

RVPH Analyst Ratings Over Time

TypeCurrent Forecast
12/17/23 to 12/16/24
1 Month Ago
11/17/23 to 11/16/24
3 Months Ago
9/18/23 to 9/17/24
1 Year Ago
12/17/22 to 12/17/23
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
2 Buy rating(s)
2 Buy rating(s)
4 Buy rating(s)
4 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$15.50$15.50$14.33$16.75
Forecasted Upside498.46% Upside1,277.78% Upside1,019.79% Upside343.12% Upside
Consensus Rating
Buy
Buy
Moderate Buy
Buy

RVPH Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

RVPH Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Reviva Pharmaceuticals Stock vs. The Competition

TypeReviva PharmaceuticalsMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.81
2.51
Consensus RatingBuyModerate BuyModerate Buy
Predicted Upside493.87% Upside29,826.34% Upside10.64% Upside
News Sentiment Rating
Positive News

See Recent RVPH News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
9/23/2024EF Hutton Acquisition Co. I
1 of 5 stars
J. Kolbert
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
8/26/2024Benchmark
3 of 5 stars
B. Jackson
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSpeculative Buy ➝ Speculative Buy$17.00 ➝ $17.00+1,688.70%
8/16/2024Maxim Group
4 of 5 stars
J. Mccarthy
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold
7/11/2024HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$14.00 ➝ $14.00+1,096.57%
10/30/2023Roth Mkm
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$12.00+112.77%
9/20/2023Roth Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
S. Henry
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 01:48 PM ET.


RVPH Forecast - Frequently Asked Questions

According to the research reports of 4 Wall Street equities research analysts, the average twelve-month stock price forecast for Reviva Pharmaceuticals is $15.50, with a high forecast of $17.00 and a low forecast of $14.00.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Reviva Pharmaceuticals in the last year. There is currently 1 hold rating, 2 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" RVPH shares.

According to analysts, Reviva Pharmaceuticals's stock has a predicted upside of 498.46% based on their 12-month stock forecasts.

Over the previous 90 days, Reviva Pharmaceuticals's stock had 1 upgrade by analysts.

Reviva Pharmaceuticals has been rated by research analysts at EF Hutton Acquisition Co. I in the past 90 days.

Analysts like Reviva Pharmaceuticals more than other "medical" companies. The consensus rating for Reviva Pharmaceuticals is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how RVPH compares to other companies.


This page (NASDAQ:RVPH) was last updated on 12/16/2024 by MarketBeat.com Staff
From Our Partners